Benazepril

Chemical formula: C₂₄H₂₈N₂O₅  Molecular mass: 424.49 g/mol  PubChem compound: 5362124

Active ingredient description

Benazepril is a prodrug which, after hydrolysis to the active substance benazeprilat, inhibits the angiotensin-converting enzyme (ACE) and so blocks the conversion of angiotensin I to angiotensin II. This reduces all the effects mediated by angiotensin II – i.e. vasoconstriction and production of aldosterone, which promotes the reabsorption of sodium and water in the renal tubules – and elevates cardiac output.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
C09AA07 Benazepril C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA07

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
LOTENSIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 86541-75-5
DrugBank Drug: DB00542
KEGG Drug: D07499
PubChem Compound: 5362124
RxNorm Ingredient: 18867
SNOMED-CT Concept: 372511001
Benazepril (substance)
UNII Identifier: UDM7Q7QWP8
BENAZEPRIL

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.